{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:20:09Z","timestamp":1761751209457,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,7]],"date-time":"2023-05-07T00:00:00Z","timestamp":1683417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jiph.2023.05.008","type":"journal-article","created":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T16:03:38Z","timestamp":1683648218000},"page":"1115-1122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A critical view on the current use of daptomycin in Spain: The daptomise study"],"prefix":"10.1016","volume":"16","author":[{"given":"Carmen Guadalupe Rodr\u00edguez","family":"Gonz\u00e1lez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther Chamorro de","family":"Vega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sof\u00eda De la Villa","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maricela Valerio","family":"Minero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Mar\u00eda Guti\u00e9rrez","family":"Urb\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro Gim\u00e9nez","family":"Manzorro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edurne Fern\u00e1ndez de Gamarra","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara Cobo","family":"Sacrist\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio Bouza","family":"Santiago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Herranz","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia Mu\u00f1oz Garc\u00eda de","family":"Paredes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Sanjurjo","family":"S\u00e1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jiph.2023.05.008_bib1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/jac\/48.4.563","article-title":"Activity of daptomycin against Gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint","volume":"48","author":"Wise","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiph.2023.05.008_bib2","unstructured":"European Public Assessment reports: Cubicin. London: European Medicines Agency. Available from: \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cubicin\u3009 Accessed 20 December 2020."},{"key":"10.1016\/j.jiph.2023.05.008_bib3","first-page":"47","article-title":"Daptomycin: an evidence-based review of its role in the treatment of Gram-positive infections","volume":"9","author":"Gonzalez-Ruiz","year":"2016","journal-title":"Infect Drug Resist"},{"issue":"6","key":"10.1016\/j.jiph.2023.05.008_bib4","first-page":"534","volume":"37","author":"Guti\u00e9rrez Urb\u00f3n","year":"2013","journal-title":"Farm Hosp"},{"issue":"11","key":"10.1016\/j.jiph.2023.05.008_bib5","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1177\/1060028021991943","article-title":"High-dose daptomycin and clinical applications","volume":"55","author":"Jones","year":"2021","journal-title":"Ann Pharmacother."},{"key":"10.1016\/j.jiph.2023.05.008_bib6","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12941-016-0130-8","article-title":"Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE","volume":"15","author":"Seaton","year":"2016","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"3","key":"10.1016\/j.jiph.2023.05.008_bib7","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/0196-6553(88)90053-3","article-title":"CDC definitions for nosocomial infections, 1988","volume":"16","author":"Garner","year":"1988","journal-title":"Am J Infect Control"},{"issue":"15","key":"10.1016\/j.jiph.2023.05.008_bib8","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","article-title":"Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American heart association","volume":"132","author":"Baddour","year":"2015","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.jiph.2023.05.008_bib9","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.eimc.2015.03.014","article-title":"Diagnosis and treatment of bacteremia and endocarditis due to Staphylococcus aureus. A clinical guideline from the Spanish society of clinical microbiology and infectious diseases (SEIMC)","volume":"33","author":"Gudiol","year":"2015","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"1","key":"10.1016\/j.jiph.2023.05.008_bib10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.medin.2017.09.012","volume":"42","author":"Chaves","year":"2018","journal-title":"Med Intensiv"},{"issue":"3","key":"10.1016\/j.jiph.2023.05.008_bib11","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eimc.2016.08.012","article-title":"Executive summary of management of prosthetic joint infections. Clinical practice guidelines by the Spanish society of infectious diseases and clinical microbiology (SEIMC)","volume":"35","author":"Ariza","year":"2017","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"6","key":"10.1016\/j.jiph.2023.05.008_bib12","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1093\/cid\/civ482","article-title":"Clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults","volume":"61","author":"Berbari","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"9237","key":"10.1016\/j.jiph.2023.05.008_bib13","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis, and management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jiph.2023.05.008_bib14","unstructured":"Standardized monitoring of consumption of antimicrobials at hospitals . VINCAT Program 2017 (Spain). Available from: \u3008https:\/\/catsalut.gencat.cat\/web\/.content\/minisite\/vincat\/documents\/objectiu_6\/Informes-ATBs\/informe-vincat-antimicrobians-dades-2017.pdf\u3009."},{"key":"10.1016\/j.jiph.2023.05.008_bib15","unstructured":"Comprehensive program for the prevention, control of healthcare-associated infections, and appropriate use of antimicrobials. PIRASOA Program 2019 (Spain). Available from: \u3008http:\/\/pirasoa.iavante.es\/pluginfile.php\/26300\/mod_resource\/content\/12\/INFORME%20PIRASOA%204T%2B%20Iras%20Anual%202019.pdf\u3009."},{"issue":"4","key":"10.1016\/j.jiph.2023.05.008_bib16","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/s10156-013-0559-z","article-title":"Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary?","volume":"19","author":"Falcone","year":"2013","journal-title":"J Infect Chemother"},{"issue":"12","key":"10.1016\/j.jiph.2023.05.008_bib17","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1007\/s12325-015-0267-4","article-title":"Evaluation of effectiveness and safety of high-dose daptomycin: results from patients included in the European Cubicin(\u00ae) outcomes registry and experience","volume":"32","author":"Seaton","year":"2015","journal-title":"Adv Ther"},{"issue":"3","key":"10.1016\/j.jiph.2023.05.008_bib18","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijantimicag.2013.05.005","article-title":"Daptomycin: the role of high-dose and combination therapy for Gram-positive infections","volume":"42","author":"Gould","year":"2013","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"10.1016\/j.jiph.2023.05.008_bib19","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/cid\/cit582","article-title":"Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia","volume":"57","author":"Falcone","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.jiph.2023.05.008_bib20","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ijantimicag.2019.08.011","article-title":"Daptomycin-containing regimens for treatment of Gram-positive endocarditis","volume":"54","author":"Russo","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"10.1016\/j.jiph.2023.05.008_bib21","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1592\/phco.31.6.527","article-title":"High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study","volume":"31","author":"Kullar","year":"2011","journal-title":"Pharmacotherapy"}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034123001624?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034123001624?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:17:35Z","timestamp":1761751055000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876034123001624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1876034123001624"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2023.05.008","relation":{},"ISSN":["1876-0341"],"issn-type":[{"type":"print","value":"1876-0341"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A critical view on the current use of daptomycin in Spain: The daptomise study","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2023.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}]}}